BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36781420)

  • 21. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
    Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
    Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.
    Noh BJ; Park YK
    Hum Pathol; 2018 Nov; 81():1-8. PubMed ID: 29944971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
    Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
    Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [H3F3A mutated multicentric giant cell tumor of bone : A very rare primary bone disease].
    Giesche JP; von Baer A; Breining T; Marienfeld R; Mellert K; Lüke J; Schultheiss M; Möller P; Barth TFE
    Pathologe; 2018 Sep; 39(5):451-456. PubMed ID: 30046846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
    Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
    Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
    Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
    Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone.
    Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Sin Y; Akane S; Sugaya J; Mori T; Fukushima S; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2021 Nov; 34(6):1899-1910. PubMed ID: 34304386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
    Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
    Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.
    Lim J; Park JH; Baude A; Yoo Y; Lee YK; Schmidt CR; Park JB; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
    Sci Rep; 2017 Oct; 7(1):13459. PubMed ID: 29044188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Giant cell tumor of bone-an update].
    Tschavoll F; Lutteri G; Leinauer B; Mellert K; Möller P; Barth TFE
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):215-219. PubMed ID: 37985483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
    Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
    Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    Lutsik P; Baude A; Mancarella D; Öz S; Kühn A; Toth R; Hey J; Toprak UH; Lim J; Nguyen VH; Jiang C; Mayakonda A; Hartmann M; Rosemann F; Breuer K; Vonficht D; Grünschläger F; Lee S; Schuhmacher MK; Kusevic D; Jauch A; Weichenhan D; Zustin J; Schlesner M; Haas S; Park JH; Park YJ; Oppermann U; Jeltsch A; Haller F; Fellenberg J; Lindroth AM; Plass C
    Nat Commun; 2020 Oct; 11(1):5414. PubMed ID: 33110075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.
    Ishihara S; Yamamoto H; Iwasaki T; Toda Y; Yamamoto T; Yoshimoto M; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Yamada Y; Kohashi K; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Kakuda Y; Nakashima Y; Oda Y
    Mod Pathol; 2022 May; 35(5):640-648. PubMed ID: 34785767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
    Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
    Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New aspects on giant cell tumor of bone].
    Lüke J; Hasenfratz M; Möller P; Barth TFE
    Pathologe; 2018 Mar; 39(2):125-131. PubMed ID: 29110035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.
    Lübbehüsen C; Lüke J; Seeling C; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Möller P; Barth TFE
    Sci Rep; 2019 Apr; 9(1):6458. PubMed ID: 31015476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.
    Scotto di Carlo F; Divisato G; Iacoangeli M; Esposito T; Gianfrancesco F
    BMC Cancer; 2018 Apr; 18(1):358. PubMed ID: 29609578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
    Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
    PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
    Kato Kaneko M; Liu X; Oki H; Ogasawara S; Nakamura T; Saidoh N; Tsujimoto Y; Matsuyama Y; Uruno A; Sugawara M; Tsuchiya T; Yamakawa M; Yamamoto M; Takagi M; Kato Y
    Cancer Sci; 2014 Jun; 105(6):744-8. PubMed ID: 24898068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.